1 Departments of Physiology and 2 Surgery, Faculty of Medicine, University of Manitoba, Manitoba, Winnipeg R3E 3J7; and 3 Unité de recherche en pneumologie, Centre de recherche de Hôpital Laval, Institut universitaire de cardiologie et pneumologie, Université Laval, Québec, Canada G1V 4G5
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Whether contractility of
bronchial smooth muscle cells (BSMC) from asthmatic subjects is
significantly altered has never been validated. We tested the
hypothesis that such BSMC show increased contractility. Cells were
isolated from endobronchial biopsies. BSMC shortening was measured
under an inverted microscope. Statistically significant increases in
maximum shortening capacity (Lmax) and velocity (Vo) were found in asthmatic BSMC
compared with normal cells. Mean
Lmax in
asthmatic BSMC was 39.05 ± 1.99% (SE) of resting cell length
compared with 28.6 ± 1.1% in normal cells; mean
Vo was 7.2 ± 0.8% of resting cell
length/s in asthmatic cells and 5.23 ± 0.46% in normal cells. To
investigate the mechanism of the increased contractility, we measured
mRNA abundance of smooth muscle types of myosin light chain kinase
(smMLCK) and myosin heavy chain. RT-PCR data revealed that smMLCK mRNA
was higher in asthmatic BSMC (0.106 ± 0.021 arbitrary
densitometric units, n = 7) than in control cells
(0.04 ± 0.008, n = 11; P < 0.05). Messages for myosin heavy chain isoforms showed no difference. Increased kinase message content is an index of the mechanism for the
increased velocity and capacity of shortening we report.
asthmatic bronchial smooth muscle contractility; smooth muscle myosin light chain kinase; single bronchial smooth muscle cell mechanics; single bronchial smooth muscle cell biochemistry
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
THE HIGH
PREVALENCE and increasing mortality of asthma have focused
research on the elucidation of its pathogenesis. Consensus in the field
is that asthma is primarily a chronic inflammatory disease.
Nevertheless the fact that 2-adrenergic agonists can relieve the respiratory distress of the acute asthmatic attack and
ameliorate that of chronic asthma suggests that besides airway inflammation, contraction of airway smooth muscle plays an important role in asthma pathophysiology. Whether the contractile properties of
human asthmatic airway smooth muscle are altered has never been
demonstrated apart from anecdotal reports in which tissues were
obtained postmortem or surgically (4, 6). The
argument that the bronchial smooth muscle cells (BSMC) are the seat of primary changes in the mechanical properties of the asthmatic airways
is supported by findings of increased maximum capacity (
Lmax) and velocity
(Vo) of shortening in BSMC obtained from our
canine model of ragweed pollen-induced allergic hyperreactivity (10). Airway smooth muscles from these animals showed no
evidence of inflammation. In human asthma, bronchospasm has been
reported in the absence of acute inflammation in exercise-induced
asthma, where bronchoalveolar lavage revealed no significant elevation in levels of inflammatory mediators and/or cells (5).
Studying the immediate and late asthmatic response, Liu et al.
(17) reported that the 5-min bronchoconstrictor response
to antigen challenge was not associated with increases in
bronchoalveolar lavage cell number nor in airway permeability,
indicating that airway smooth muscle contraction plays a predominant
role in the immediate asthmatic response. On the other hand, airway
inflammation has been found in cases of very mild asthma and also in
subjects with increased airway reactivity but no asthma symptoms
(14, 15). In this latter group, the airway inflammation
increased over a 2-yr period and was more important in those who
developed symptoms of asthma (15). These observations
suggested that, in human asthma, there is an asymptomatic period in
which inflammation induces airway hyperreactivity; when this process
intensifies, symptoms appear. Consequently, although its relation with
airway inflammation is not well defined, airway contractility is likely
a major component of asthma pathogenesis, and, in the present study, we
postulated that BSMC from asthmatics show increased contractility
compared with cells from normal subjects.
We have previously reported that airway smooth muscle myofibrillar Mg2+-ATPase activity is increased in ragweed pollen-sensitized dogs compared with unsensitized animals (13). In that study, sensitized dog airway smooth muscles presented no increase in myosin heavy chain (SM)-A content that includes myosin heavy chain-1 (SM-1) and -2 (SM-2) isoforms; increased total content of smooth muscle myosin light chain kinase (smMLCK) was detected. This kinase was of the smooth muscle type with a molecular mass of 108 kDa (smMLCK-108). It stimulated actin-activated myosin Mg2+-ATPase activity via phosphorylation of the 20-kDa myosin light chain (MLC20). As expected, these smooth muscles also presented an increased phosphorylation of the regulatory MLC20 (13). Consequently, smMLCK-108 is likely an important enzyme regulating smooth muscle contractility and mediating increased BSMC contractility in asthma. Another myosin heavy chain isoform, SM-B, has been recently described; it has a unique seven-amino acid insert in its amino-terminal head and possesses twice the ATPase activity and Vo of SM-A (12, 27). Alterations in the content of this isoform may be present in asthmatic BSMC, and these may be mediating increased cell contractility.
The specific aims of this project were to measure the
Lmax and Vo of
isolated BSMC obtained from endobronchial biopsy samples from
asthmatics and controls and to investigate the underlying molecular
mechanisms by measuring the abundance of mRNA for smMLCK-108, SM-A, and
SM-B. This study provides statistically significant evidence of an
increased contractility in human asthmatic BSMC and indicates that this
is likely mediated by increased total activity and content of
smMLCK-108.
![]() |
MATERIALS AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Selection and evaluation of subjects. The mechanical and biochemical studies were conducted on endobronchial biopsies from two subpopulations randomly selected from a defined, homogeneous parent population of mild to moderately severe asthmatics whose ages (with two exceptions aged 44 and 48 yr) ranged from 18 to 28 yr. The paucity of BSMC obtained from a given subject necessitated the two samples, because the biophysical and biochemical analyses could not be conducted on cells from the same sample. The two samples were matched as closely as possible.
Fifteen allergic or nonallergic nonasthmatic subjects (control group) and 12 subjects with asthma (test group) were recruited to this study. Table 1 provides details of subjects whose endobronchial biopsies were used for single cell contractility studies. Five were nonasthmatic, and five were asthmatic. Table 2 provides details of subjects whose biopsies were used for RT-PCR studies; 11 were nonasthmatic, and seven were asthmatic. One control was subjected to two bronchoscopies: one for contractility and the other for myosin and kinase mRNA measurements. Nonasthmatic subjects had no history of asthma nor of taking any medication for that disease, no occupational exposure to sensitizing agents, and no history of disease, except for numbers 6-11, who suffered from allergic rhinitis (Table 2). In asthmatic subjects, the diagnosis was made according to the definition of the American Thoracic Society (1, 2). With two exceptions who were on steroids, only subjects who were taking inhaled
|
|
Bronchoscopy and bronchial biopsy process. Before bronchoscopy, a 200-µg dose of salbutamol was given to the asthmatic subjects via a metered-dose inhaler (Glaxo Wellcome, Mississauga, Canada) when their FEV1 was <75% of predicted. Oxygen was administered, and vital signs, electrocardiogram, and oximetry were monitored throughout the endoscopy. After local anesthesia of the throat, larynx, and trachea with 4% lidocaine, a flexible bronchoscope (Olympus OES 10 fiberscope; Olympus, Markham, Canada) was introduced into the bronchial tree. Bronchial anesthesia was completed with lidocaine up to a total dose of 400 mg using either a 2 or 4% solution of lidocaine. Six to eight specimens were taken from the origins of segmental or lobar carinae of the right lung using alligator forceps. After the bronchoscopy, inhaled salbutamol was administered if necessary and subjects were kept under observation until it was felt they could safely resume normal activity. For evaluation of BSMC contractility, the bronchial specimens were suspended in modified low-calcium Krebs solution, pH 7.4, and kept on ice until processed. They were sent by plane to Winnipeg for contractility studies. In all cases the entire procedure was completed within 24 h. For mRNA measurements, bronchial biopsies were rapidly frozen and sent, on dry ice, to Winnipeg. On arrival they were thawed to 22°C in normal Ca2+ (1.6 mM) containing Krebs-Henseleit solution and bubbled with a 5% CO2-95% air gas mixture.
Preparation of contractile bronchial smooth muscle cells. From each subject, all bronchial samples were pooled and incubated in Hanks' solution with 10 mM taurine, 400 units/ml collagenase, 30 units/ml papain, 1 mg/ml BSA, and 1 mM DTT for 45 min. After enzymatic digestion, the tissue was washed with Ca2+-free Krebs-Henseleit solution several times, and cells were finally dispersed by gentle trituration with Ca2+-free Krebs solution using a Pasteur pipette; they were stored on ice for study within 6 h. Most freshly isolated cells appeared fully relaxed with smooth and shining sarcolemmal membranes under an inverted microscope. Ninety-five percent of the cells isolated were viable as judged by their ability to exclude trypan blue, their typical fusiform shape determined by light microscopy, and their ability to shorten by 25-40% on electrical field stimulation (EFS) of optimal current density. Addition of relaxants such as norepinephrine, atropine, isoproterenol, and nitroglycerin did not cause further relaxation of cells. These cells showed a reversible shortening response to acetylcholine, histamine, KCl, and single-pulse electrical stimulation. The degree of shortening seen in all cells ranged from 25 to 40% of initial resting cell length. This amount of reversible shortening is not present in fibroblasts, myofibroblasts, lymphocytes, or macrophages. Addition of taurine in enzymatic solution was critical; isolated cells did not show any contractile response without taurine, even though they appeared structurally normal under the microscope (S. Sim, University of Western Ontario, personal communication). Because the cells were unloaded, i.e., external load was zero, relaxation took 20-30 min to develop at room temperature. Cells deteriorated more rapidly after chemical stimulation than after EFS. For this reason, EFS was used in the current study. Furthermore chemical stimulation activated all BSMC in a field with considerable variability. With EFS only the single cell adjacent to the stimulating electrode is activated. Any other BSMC in the field remained relaxed and available for subsequent study. It must be remembered also that EFS acts by releasing acetylcholine from the terminal neural filaments in the muscle strip; EFS from this point of view is the most physiological stimulus to use. Atropine added to the bath completely blocks the EFS response.
Measurement of single cell contraction.
All studies on isolated BSMC were conducted at room temperature
(22°C). Freshly isolated cells were placed in a custom-designed chamber containing 1 ml of aerated Krebs-Henseleit solution at 22°C
and allowed to settle for 5 min, after which the chamber was slowly
perfused with fresh, aerated Krebs-Henseleit solution. Cell length was
measured with an inverted microscope fitted with a graticule. For
analysis of length distribution, lengths of all smooth muscle cells in
a field were measured except for those with obvious contracture, which
could be clearly recognized by the presence of membranous blebs
pouching out from the sarcolemma. Shortening capacity of single cells
was measured by applying a 10-Hz, 35-V, 1-ms-long bipolar
electric pulse stimulation, with one spot electrode placed ~10 µm
away from the cell and the other at a random position in the chamber.
This single pulse elicited a shortening response that was 85% of the
maximal response to acetylcholine (104 M). The shortening
response to the single electrical pulse was fully reversible as stated
above. Stimulation with 10
4 M acetylcholine produced a
contraction 20% greater than that elicited by EFS; 80 mM KCl produced
a contraction almost equal to that of EFS. However, these contractions
were not fully reversible and were not used in subsequent experiments.
Throughout the experiment, images of the cells were monitored and
recorded by a closed-coupled device video camera mounted on the
microscope. The images were then digitized and analyzed with an
in-house-designed computer program for derivation of
Lmax and Vo.
Vo represents zero-loaded isotonic shortening.
To obtain this measurement, the cell was gently lifted off the bottom
of the glass chamber. One end was held in a glass microclamp while the
other end remained free. The entire cell was held under the surface of
the perfusing solution but was not allowed to touch the glass surface.
Vo was measured from the digitized shortening
vs. time curve. As is usual in the field, the slope of the curve at 100 ms after onset of shortening was identified as
Vo. It is to be noted that from a given patient 10-20 airway smooth muscle cells were isolated. These contracted reversibly to EFS, which was the basis for their selection for measurement of velocity (Vo) and capacity
(
Lmax) of shortening. Nonmuscle cells, e.g.,
epithelial, lymphocyte, fibroblasts, and macrophages, shorten at most
by 5% of their initial length. Moreover, the shortening is irreversible.
Measurement of mRNA of smMLCK-108 and myosin heavy chain (SM-A and SM-B): isolation of total mRNA. From the endobronchial biopsies obtained from subjects described in Table 2 and using the method described above, we isolated BSMC and viewed them under the microscope. Their fusiform morphology and their shortening response to electrical stimulation, as stated before, identified them. The cells obtained from a given asthmatic or control subject were homogenized in 75 µl of TRIzol reagent. To this was added 75 µl of chloroform; the mixture was shaken well and then centrifuged. The aqueous phase was collected, isopropanol was added, and the resulting mixture was spun down. The pellet obtained was washed with ethanol, dried, and then brought into solution with 4 µl of diethylpyrocarbonate-treated water. An alternate procedure was to simply homogenize all the biopsy samples obtained from a given patient. The mRNA from the homogenate total RNA was isolated, and RT-PCR was carried out as described below. The rationale for this procedure was that only smMLCK-108 mRNA was found to be amplified in pilot experiments. Because this message is present only in mature smooth muscle cells, contamination from nonmuscle cells such as epithelial cells, fibroblasts, and macrophages was ignored as these contain nonmuscle-type MLCK (nmMLCK-210) alone, which has low specific activity.
RT-PCR. One microliter of oligo dT (100 ng/µl) was added to 9 µl of the above mRNA solution and incubated at 70°C for 5 min; a further 5-min incubation was conducted under ice-cold conditions. To this was added the following solution: 10 µl 5× RT buffer (GIBCO), 5 µl 0.1 M DTT, 4 µl 10 mm dNTP, 1 µl RNase inhibitor, 17.5 µl sterile water, 2.5 µl 200 U/µl Moloney murine leukemia reverse transcriptase (M-MLV-RT, GIBCO). This total volume was mixed well and then incubated at 37°C for an hour and a half. Thereafter the tube was placed in 95°C water for 5 min to stop the reaction. Five microliters of the reaction solution were taken for the PCR. The smMLCK-108 mRNA primers were as follows: upstream: 5'-GAAATTAGGATCTGGGAAATTTCGACAG-3' and downstream: 5'-CAATGTTCGTATCTTTCATTAGCC- 3'. We used 50 µl of PCR reaction solution. It contained 10 µl 5× PCR buffer (Boehringer Mannheim, Quebec, Canada), 4 µl 10 mM dNTP, 1 µl upstream primer, 1 µl downstream primer, and 1 µl enzyme mixture (Boehringer Mannheim). Sterile water was added to make a final volume of 50 µl and then mixed carefully. According to the thermocycler temperature protocol, reaction solution was heated at 95°C for 2 min to obtain a hot start; 90°C denaturation was carried out for 30 s, 55°C annealing for 30 s, and 72°C for 45 s, and primer extension for 40 cycles followed by incubation for 7 min at 68°C to provide adequate elongation. Dr. Ian Dixon, a departmental colleague, kindly synthesized the primers. The procedure just described was also carried out for myosin heavy chain, along with GAPDH analysis (19). The myosin heavy chain message primers were as follows: upstream: 5'-GTCATCCAGTACCTGGCCG-3' and downstream: 5'-GTCATTGACCGTCTTG-3'. The primers for GAPDH were: upstream: 5'-TGAAGGTCGGTGTCAACGAT-3' and downstream: 5'-CATTGAGGGCATGAGGTCCACCAC-3'. The products of the PCR were separated on 1.5% agarose gel and visualized by staining with ethidium bromide under ultraviolet light. The primers were a generous gift from Drs. R. S. Adelstein and S. Kelley of the National Institutes of Health (Bethesda, MD).
Data analysis. Data were expressed as means ± SE. Cell shortening velocity and capacity were expressed in normalized units with respect to initial cell length. Analysis of variance (ANOVA) was employed to analyze the differences of mean values among different groups. Duncan's new multiple-range test (8) was used as a complementary analysis to the ANOVA to determine which differences between means were significant (P < 0.05). The unpaired two-tailed Student's t-test (7) was used to compare mean values between two groups as needed. Two different populations of normal and asthmatic subjects were used to obtain biopsies for the mechanical and the RT-PCR. The two samples of asthmatics and of nonasthmatics were obtained randomly. Nonparametric statistical analysis (Wilcoxon's test) was carried out to compare the two subgroups of nonasthmatic subjects and the two subgroups of asthmatic subjects.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Subjects' characteristics.
Subjects' characteristics are presented in Tables 1 and 2.
Nonasthmatic nonallergic (n = 9) and allergic
(n = 6) subjects had normal spirometry parameters and
PC20 values. Ten asthmatics had FEV1 >75% of
predicted and were using 2-agonists alone occasionally. Their PC20 was measured at the time of evaluation. Two
others had mildly uncontrolled asthma. They were taking inhaled
2-agonist alone on demand at the time of the
bronchoscopy, but their PC20 was measured after the
bronchoscopy and a regular use of inhaled steroids. It was not possible
to conduct both sets of measurements on cells obtained from the same
subjects, as their number (10-20 cells) was too small, and all
biopsies were used for BSMC isolation. In the first group of subjects
(Table 1), only mechanical studies were conducted; in the second group
(Table 2), only RT-PCR studies were conducted. Nonparametric
(Wilcoxon's two-sample test) analysis showed no significant difference
(P > 0.05) among the relevant variables (age, sex,
forced vital capacity percent, FEV1%, PC20) in
the two nonasthmatic groups and the two asthmatic groups.
Contractile properties of human airway smooth muscle cells. As stated above, usually 10-20 contractile cells were isolated from the total number of bronchoscopy biopsies obtained from each subject. The means for asthmatics and controls were 15 ± 3.1 (SE) and 12 ± 2.9, respectively. This represented ~5% of the total number of cells in 0.5 mm3 of bronchial airway wall tissue. This figure was obtained by morphometry of a histological tissue section. Freshly isolated BSMC appeared elongated with smooth and shining sarcolemma under an inverted phase-contrast microscope. These cells showed a reversible contraction in response to low-level single-pulse EFS. Maximal contraction could be induced with repeated-pulse electrical stimulation. It was ~15% greater than the response to a single pulse but was irreversible. BSMC demonstrated a mean length of 70 ± 5 µm at full relaxation for both asthmatic and control subjects.
Figure 1A shows isotonic shortening of an essentially zero-loaded, electrically stimulated single human BSMC from a normal subject, measured at room temperature (22°C). At 4 s, shortening is 50% complete. At 37°C (data not shown), the shortening is almost equal to 75% at 4 s and equal to that of canine BSM strips previously reported by us (see Fig. 6 in Ref. 23). Initial experiments on human BSMC conducted at 37°C revealed deterioration of cell condition. At 22°C stability was very good. For this reason and for the fact that the biochemical studies were conducted at 22°C, this was the temperature selected for the experiments. From data such as this, contractility as assessed by measuring
|
Molecular mechanism for the increased shortening of asthmatic
airway smooth muscle.
To investigate the molecular mechanism for the increased
Vo that we report here, we measured the
abundance of the messenger RNA for smMLCK-108. Figure
2 shows results for smMLCK-108 mRNA. Lane 1 shows molecular weight markers, lanes
2-7 show bands from asthmatic subjects, whereas bands
8-10 are from nonasthmatics. The average density of the bands
in lanes 2-7 is greater than that of the average
density of bands in lanes 8 and 10. Similar results were obtained with the other asthmatic and the two normal subjects. We conclude that the content of mRNA for smMLCK-108 is
significantly greater in asthmatics. The mean values expressed in
arbitrary units and corrected for GAPDH density were 0.1056 ± 0.021 for asthmatic subjects (n = 7) and 0.040 ± 0.008 for controls (n = 5). The difference was
significant (P < 0.05).
|
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Changes in contractile properties of the asthmatic bronchial smooth
muscle cells.
We reported that airway smooth muscle strips from sensitized animals
demonstrate increased Vo and
Lmax (11, 24). We now report
similar alterations in intrinsic contractile properties of single BSMC
obtained from airways of asthmatic subjects. Moreover, the RT-PCR
analysis of asthmatic BSMC showed increased expression of
smMLCK-108 mRNA suggesting a molecular basis for the observed change in contractility.
Measurement of Vo. The exact measurement of Vo in smooth muscle has not been easy. In skeletal muscle where single crossbridge mechanics can be measured, the T2 transient reported by Huxley and Niedergeke (9) provides records for valid Vo measurement. In strips of striated and smooth muscle, the problem is that the initial part of the shortening is artefactual because of the presence of lever overshoot. At later points in time, the velocity is artefactually slow as the internal resistor of the cell becomes compressed and loads the contractile element internally, leading to a spuriously low Vo. Stephens et al. (23) published data describing the compliance of the internal resistor for smooth muscle. The results indicate that by 300-500 ms the resistor would load the contractile element significantly. No real solution to the problem of how to measure Vo exactly exists, and currently we measure Vo at 100 ms after onset of shortening in human and canine BSMC.
Role of increased shortening velocity (Vo) in the
production of bronchospasm and the relationship between Vo
and Lmax.
In RESULTS we presented data indicating
Vo was significantly increased in asthmatic
BSMC. In contracting canine smooth muscle strips whose contraction time
is 10 s (24), at 37°C, >75% of the measured
shortening is completed within the first 1.5 s. Similar results
are observed with human BSMC, where 50% of the shortening at 22°C
(Fig. 1) and 75% at 37°C are complete within 4 s.
Molecular mechanism underlying increased contractility of the BSMC. The molecular mechanisms of increased contractility of asthma BSMC are currently unknown. The major difficulty, as pointed out before, stemmed from the limitation in obtaining sufficient tissue from subjects for biochemical studies. Previous studies from sensitized canine airway smooth muscle strips indicated that increased expression of protein content of smMLCK-108 accounted for the increased contractile properties of the muscle (11), which are mainly regulated by this enzyme. It must be remembered that unlike striated muscle, smooth muscle myosin ATPase is a very weak ATPase and is stimulated in a graded manner by phosphorylation of the MLC20. Stephens and Jiang (22) recently provided confirmatory evidence for this in airway smooth muscle by showing that the in vitro motility of actin filaments by smooth muscle myosin heads was related in a dose-response manner to the concentration of smMLCK. This substantiates the idea that at resting states the actomyosin ATPase has weak activity but increases it in a graded manner by increasing activity of the kinase. Increased smMLCK content has also been reported by others in passively sensitized human airway smooth muscles (3). Our RT-PCR studies conducted on isolated cells suggest that the mechanism responsible for the increased contractility of single asthmatic airway smooth muscle is associated with increased abundance of the smMLCK-108 message. If one assumes that the content of the expressed protein is a function of the abundance of message abundance, our findings would explain the increased contractility of the asthmatic airway smooth muscle cell. Furthermore, support for this conclusion is obtained from our canine experiments (11), in which bronchial and tracheal smooth muscle strips from ragweed pollen-sensitized animals showed the same qualitative and quantitative increases in maximum velocity and capacity of shortening as shown here by the single cells obtain from bronchi of human asthmatics. The canine tissues showed increases in total MLCK content. In these experiments the protein was measured directly by Western blots and specific antibodies. Thus the human MLCK mRNA and the canine MLCK protein contents showed the same directional changes. The fact that specific activity of the kinase is unchanged with sensitization (11) indicates that the molecule and its intrinsic activity are unchanged. However, the increased total content would produce phosphorylation of increased amounts of the MLC20 and increased actin-activated, i.e., myosin Mg2+, ATPase activity. Another possible reason for the increased content is a change in the stability of the protein. Turnover studies to evaluate this possibility are planned for the future in strips of bronchial smooth muscle since the study is not feasible in single cells.
With respect to the validity of the RT-PCR measurements, it must be acknowledged that sequencing studies of the product were not carried out. However, since we detected only one band we surmised that nonspecific messages were not copied. Furthermore the number of base pairs in the band matched those expected for smMLCK message. Another question relates to the contribution of nonmuscle MLCK of molecular mass 210 (nmMLCK-210) to the overall phosphorylation. We have reported (16) that in canine sensitized smooth muscle, the content of nmMLCK-210 is <15% of total MLCK and that the phosphorylation it produces is >30% of the maximal phosphorylation produced. We conclude that the role of nmMLCK-210 in sensitized airway smooth muscle is minor. Differences in amount and distribution of smooth muscle myosin heavy chain isoenzymes would also affect smooth muscle contractile properties. In sensitized canine airway smooth muscle, no increase in SM-A expression was found, and SM-B was absent. We found no increase in expression of SM-A in human asthmatic airway smooth muscle and no expression of SM-B. Kelley et al. (12) have reported that SM-B is present only in phasic smooth muscle. They and others have shown that only SM-A is present in tonic smooth muscle (21). Consequently, the absence of SM-B expression in human airway smooth muscle was not unexpected, since this muscle is of tonic type. Proteins such as tropomyosin, calponin, caldesmon, and the 17-kDa essential myosin light chain are also important in regulation of smooth muscle contraction. Their roles in sensitized bronchial smooth muscle need further investigation. In conclusion, the endobronchial biopsy technique enables adequate numbers of subjects to be sampled to allow conclusions to be made with statistical significance. The present study demonstrates that human asthmatic BSMC possess significantly increased contractile properties compared with control BSMC. Moreover it suggests that one likely cause for this increase is the presence of an increased BSMC content of smMLCK, which brings about increased actomyosin ATPase activity and bronchospasm. The smMLCK protein content could not be measured in the 10-20 cells obtained from each subject because of technical difficulty. However, the RT-PCR measurements that were performed showed that the message was significantly increased, and assuming that its stability is not changed and that the message could be used as an indicator of protein content, we concluded that the biochemical changes accounted for the increased contractility of BSMC obtained from asthmatic subjects. Further support for this conclusion is obtained from our canine experiments, in which bronchial and tracheal smooth muscle strips from ragweed pollen-sensitized animals showed almost exactly the same qualitative and quantitative increases in Vo and Lmax as were shown by the single cells obtained from human asthmatics. The canine tissues showed increases in total smMLCK content. In these experiments the protein was measured directly by Western blots using specific antibodies. Thus the human smMLCK mRNA and the canine smMLCK protein contents showed the same directional changes. ![]() |
ACKNOWLEDGEMENTS |
---|
Thanks are due to Dr. R. S. Adelstein and C. Kelley of the Cardiovascular Division of the National Institutes of Health (Bethesda, MD) for carrying out an RT-PCR analysis of the messages for myosin heavy chains and to Dr. Ian Dixon for sequencing the myosin light chain kinase nucleotide primers.
![]() |
FOOTNOTES |
---|
This work was supported by operating grants from the Childrens' Hospital Research Foundation. X. Ma was the recipient of a studentship from the Manitoba Health Research Council. Y. Wang was a research fellow from Norman Bethune University of Medical Sciences of China.
Address for reprint requests and other correspondence: N. L. Stephens, Univ. of Manitoba, Dept. of Physiology, 425BMSB, 730 William Ave., Winnipeg, Manitoba, Canada R3E 3J7 (E-mail: nstephe{at}ms.umanitoba.ca).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
June 27, 2002;10.1152/ajplung.00389.2001
Received 13 March 2001; accepted in final form 30 May 2002.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1.
American Thoracic Society.
Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma.
Am Rev Respir Dis
136:
225-234,
1987[ISI][Medline].
2.
American Thoracic Society.
Snowbird workshop on standardization of spirometry.
Am Rev Respir Dis
119:
831-838,
1979[ISI][Medline].
3.
Ammit, AJ,
Armour CL,
and
Black JL.
Myosin light chain kinase content is increased in human sensitized airway smooth muscle (Abstract).
Am J Respir Crit Care Med
155:
A370,
1997.
4.
Bramley, A,
Thomson RJ,
Roberts CR,
and
Shellenberg RR.
Hypothesis: excessive bronchoconstriction in asthma is due to decreased airway elastance.
Eur Respir J
7:
337-341,
1994
5.
Broide, DH,
Eisman S,
Ramsdell JW,
Ferguson P,
Schwartz LB,
and
Wasserman SI.
Airway levels of mast cell-derived mediators in exercise-induced asthma.
Am Rev Respir Dis
141:
563-568,
1990[ISI][Medline].
6.
DeJongste, JC,
Mons H,
Bonta IL,
and
Kerrebijn KF.
Human asthmatic responses in vitro.
In: Human Airway Smooth Muscle. Den Haag: CIP-Data Koninklijke Bibliotheek, 1986, p. 167-177.
7.
Dixon, WJ,
and
Massey FJ.
Introduction to Statistical Analysis. New York: McGraw-Hill, 1983.
8.
Duncan, DB.
A significance test for differences between ranked treatments in analysis of variance.
Virginia J Sci
2:
171-189,
1951.
9.
Huxley, AF,
and
Niedergeke R.
Structural changes in muscle during contraction.
Nature
173:
971-973,
1954[ISI][Medline].
10.
Jiang, H,
Rao K,
Halayko AJ,
Kepron W,
and
Stephens NS.
Bronchial smooth muscle mechanics of a canine model of allergic airway hyperresponsiveness.
J Appl Physiol
69:
120-126,
1992
11.
Jiang, H,
and
Stephens NL.
Ragweed sensitization induced increase of myosin light chain kinase content in canine airway smooth muscle.
Am J Respir Cell Mol Biol
7:
567-573,
1992[Medline].
12.
Kelley, CA,
Takahashi JR,
Yu JH,
and
Adelstein RS.
An insert of seven amino acids confers functional differences between smooth muscle myosins from the intestines and vasculature.
J Biol Chem
268:
12848-12854,
1993
13.
Kong, SK,
Halayko AJ,
and
Stephens NL.
Increased phosphorylation of myosin in sensitized canine tracheal smooth muscle.
Am J Physiol Lung Cell Mol Physiol
259:
L53-L56,
1990
14.
Laprise, C,
and
Boulet L-P.
Asymptomatic airway hyperresponsiveness: a three-year follow-up.
Am J Respir Crit Care Med
156:
403-409,
1997
15.
Laprise, C,
Laviolette M,
Boutel M,
and
Boulet L-P.
Asymptomic airway hyperresponsiveness: relationships with airway inflammation and remodelling.
Eur Respir J
14:
63-73,
1999
16.
Liu, G,
and
Stephens NL.
Comparison of relative activities of smooth muscle type (SM-) and non-muscle (NM-) myosin light chain kinase (MLCK) (Abstract).
Am J Respir Crit Care Med
161:
A696,
2000.
17.
Liu, MC,
Hubbard W,
Proud D,
Steadly BA,
Galli SJ,
Sobotka AK,
Bleecker BR,
and
Lichenstein LM.
Immediate and late inflammatory responses to ragweed antigen challenge of the peripheral airways in allergic asthmatics. Cellular, mediator and permeability changes.
Am Rev Respir Dis
144:
51-58,
1991[ISI][Medline].
18.
Ma, X,
and
Stephens NL.
The cytoskeleton and the extracellular matrix in sensitized canine tracheal smooth muscle.
Respir Physiol
110:
57-66,
1997[ISI][Medline].
19.
Meer, DP,
and
Eddinger TJ.
Heterogeneity of smooth muscle myosin heavy chain expression at the single cell level.
Am J Physiol Cell Physiol
270:
C1819-C1824,
1996
20.
Shirazi, A,
Iizuka K,
Fadden P,
Mosse C,
Somlyo AP,
Somlyo AV,
and
Haystead TA.
Purification and characterization of the mammalian myosin light chain phosphatase holoenzyme. The differential effects of the holoenzyme and its subunits on smooth muscle.
J Biol Chem
269:
31598-31606,
1994
21.
Siegman, MJ,
Butler TM,
Mooers SU,
Trinkle-Mulcahy L,
Narayan S,
Adam L,
Chacko S,
Haase H,
and
Morano I.
Hypertrophy of colonic smooth muscle: contractile proteins, shortening velocity, and regulation.
Am J Physiol Gastrointest Liver Physiol
272:
G1571-G1580,
1997
22.
Stephens N and Jiang H. Velocity of translation of single actin
filaments (AI) by myosin heads from antigen-sensitized airway smooth
muscle cells. Mol Cell Biochem. In press.
23.
Stephens, NL,
Kong SK,
and
Seow CY.
Mechanisms of increased shortening of sensitized airway smooth muscle.
In: Mechanisms in Asthma, edited by Black J.. New York: Liss, 1988, p. 231-254.
24.
Stephens, NL,
Wang Y,
Li W,
and
Ma X.
Airway hyperreactivity: direct smooth muscle approach.
Pulm Pharmacol Ther
12:
97-101,
1999[ISI][Medline].
25.
Tanaka, J,
Ito M,
Feng J,
Ichikawa K,
Hamaguchi T,
Nakamura M,
Hartshorne DJ,
and
Nakano T.
Interaction of myosin phosphatase target subunit 1 with the catalytic subunit of type 1 protein phosphatase.
Biochemistry
37:
16697-16703,
1998[ISI][Medline].
26.
Weersink, EJ,
Aalbers R,
Koeter GH,
Kauffman HF,
DeMonchy JG,
and
Postma DS.
Partial inhibition of the early and late asthmatic response by a single dose of salmeterol.
Am J Respir Crit Care Med
150:
1262-1267,
1994[Abstract].
27.
White, S,
Martin AF,
and
Periasamy M.
Identification of a novel smooth muscle myosin heavy chain cDNA: isoform diversity in the S1 head region.
Am J Physiol Cell Physiol
264:
C1243-C1258,
1993.